3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumors
1
Sarcoma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Liver Neoplasms
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Castration Resistant Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Sunitinib
4
Cyclophosphamide
4
Capecitabine
4
Bevacizumab
4
pazopanib
3
Topotecan
3
Paclitaxel
3
Docetaxel
3
Carboplatin
3
temsirolimus
2
liposomal doxorubicin
2
fludarabine
2
Sorafenib
2
Panobinostat
2
NVP-BKM120
2
Lapatinib
2
Irinotecan
2
Immune Checkpoint Inhibitors
2
Gemcitabine
2
Everolimus
2
Erlotinib Hydrochloride
2
Doxorubicin
2
Bortezomib
2
vadimezan
1
spartalizumab
1
somatostatin receptor 2
1
selinexor
1
selicrelumab
1
perifosine
1
pegylated granulocyte colony-stimulating factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Solid Tumors
×
TH 302
×
Clear all
NCT01485042
2017-09-01
PATH
Duke University
Phase 1
Completed
50 enrolled